导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -13.72% | 4038/4773 |
| 近一周 | -2.69% | 4157/5465 |
| 近一月 | -1.07% | 1016/5421 |
| 近一季 | -1.41% | 1207/5231 |
| 近半年 | -5.68% | 3070/4920 |
| 近一年 | -12.32% | 3538/4394 |
| 近两年 | 30.81% | 2246/2954 |
| 近三年 | 15.49% | 1628/2253 |
| 成立以来 | 6.56% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-14.81% 4680/4961 |
3.53% 2940/5312 |
- - |
- - |
| 2025 | 9.86% 2850/4813 |
-5.88% 3323/3635 |
6.08% 491/4076 |
7.92% 3428/4524 |
1.95% 1136/4813 |
| 2024 | 32.63% 82/3463 |
-3.37% 1495/2808 |
-4.47% 1512/3014 |
43.29% 12/3129 |
0.27% 1240/3463 |
| 2023 | 0.72% 395/2656 |
2.42% 1355/2280 |
-0.75% 413/2385 |
6.66% 69/2515 |
-7.10% 2049/2655 |
| 2022 | -19.62% 873/2207 |
-15.54% 1048/1919 |
2.11% 1354/2016 |
-13.96% 1000/2113 |
8.32% 266/2208 |
| 2021 | -11.14% 1104/1822 |
-13.14% 1153/1255 |
1.23% 1064/1330 |
-0.69% 501/1466 |
1.76% 808/1822 |
| 2020 | 17.60% 760/1250 |
-12.22% 879/1028 |
8.24% 828/1067 |
20.27% 58/1164 |
2.91% 958/1184 |
| 2019 | 48.51% 113/1092 |
41.50% 38/739 |
-1.96% 334/788 |
-1.21% 638/850 |
8.37% 321/918 |
| 2018 | -23.72% 296/834 |
- - |
-12.63% 401/631 |
2.82% 96/660 |
-6.77% 52/682 |
| 2017 | 12.19% 283/714 |
- - |
- - |
- - |
- - |
| 2016 | -13.34% 320/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 天弘中证证券保险C VS. 长安沪深300非周期A(740101) |